Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-06-30
2011-10-25
Aeder, Sean (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
08043819
ABSTRACT:
The present invention relates to a method for discrimination of p16INK4aoverexpressing metaplasias from neoplastic or preneoplastic p16INK4aoverexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 and/or HPV E7 molecules in biological samples in the course of cytological testing procedures. The method thus enables for reduction of false positive results in the p16INK4abased detection of anogenital lesions in cytological testing procedures.
REFERENCES:
patent: 4281061 (1981-07-01), Zuk et al.
patent: 5723313 (1998-03-01), Sherr et al.
patent: 5876965 (1999-03-01), Sherr et al.
patent: 6033847 (2000-03-01), Sherr et al.
patent: 6172194 (2001-01-01), Sherr et al.
patent: 6303323 (2001-10-01), Laskey et al.
patent: 6316208 (2001-11-01), Roberts et al.
patent: 6407062 (2002-06-01), Sherr et al.
patent: 6482929 (2002-11-01), Sherr et al.
patent: 7361460 (2008-04-01), Williams et al.
patent: 7422859 (2008-09-01), Ridder et al.
patent: 2002/0106685 (2002-08-01), Henning et al.
patent: 2003/0143646 (2003-07-01), Laskey et al.
patent: 2003/0157482 (2003-08-01), Keesee et al.
patent: 2007/0243552 (2007-10-01), Williams et al.
patent: 1025444 (2000-08-01), None
patent: 1 217 377 (2002-06-01), None
patent: 1 387 173 (2004-02-01), None
patent: WO 97 12060 (1997-04-01), None
patent: WO 9921014 (1999-04-01), None
patent: WO 00 01845 (2000-01-01), None
patent: WO 01 40300 (2001-06-01), None
patent: WO 02 08764 (2002-01-01), None
patent: WO 2004 013631 (2004-02-01), None
Buskens et al (Digestive Disease Week Abstracts and Itinerary Planner, 2003, abstract No. 850).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Solomon et al. (2001, J. of the National Cancer Institute 93(4):293-299).
Guccione (Virology 293:20-25 (2002).
Khan et al, Journal of Virology, Jun. 1993, 67(6): 3396-3403).
von Knebel Doeberitz (2001, Dis. Markers 17(3):123-8 (abstract only).
Klaes et al. (2001, Int. J. Cancer 92:276-284).
Parker et al (Gynecological Oncology, 1997, 64: 242-251).
von Knebel Doeberitz (2001, Dis. Markers 17(3):123-8).
He, et al., “Expression, Deletion and Mutation of p16 Gene in Human Gastric Cancer” World J. of Gastroenterology 7(4): 515-521 (2001).
Myung, et al., “Loss of p16 and p27 Is Associated With Progression of Human Gastric Cancer” Cancer Letters 153:129-136 (2000).
Nakao et al., “Induction of p16 During Immortalization HPV 16 and 18 and Not During Malignant Transformation” British J of Cancer 75(10):1410-1416, 1997.
O'Nions, et al., “p73 Is Over-Expressed in Vulval Cancer Principally As the .DELTA.2 Isoform” British J. Cancer 85(10):1551-1556 (Nov. 2001).
Sano, et al., “Overexpression of P16 and P14ARF Is Associated With Human Papillomavirus Infection in Cervical Squamous Cell Carcinoma and Dysplasia” Pathology Int. 52:375-383 (May 2002).
Sherr, “The Ink4a/Arf Network in Tumor Suppression” Nature Reviews Mol. Cell Bio 2:731-737, (2001).
Takeuchi, et al., “Altered p16/MTSI/CDKN2 and Cycling D1/PRAD-1 Gene Expression Is Associated With the Prognosis of Squamous Cell Carcinoma of the Esophagus” Clinical Cancer Research 3:2229-2236, (1997).
Tsujie et al., “Expression of Tumor Suppressor Gene p16INK4 Products in Primary Gastric Cancer”Oncology, vol. 58, 126-136 (2000).
Sano et al., “Expression Status of p16 Protein is Associated with Human Papillomavirus Oncogenic Potential in Cervical and Genital Lesions,”Am. J. Pathol., vol. 153, No. 6, 1741-1748 (1998).
Riethdorf S et al: “Analysis of p16/MTS1 . . . ”, Virchows Archiv, vol. 439, No. 3, Sep. 2001, p. 338.
Milde-Langosch Karin et al: “Expression of cyclin-dependent kinase inhibitors . . . ”, Virchows Archiv, vol. 439, No. 1, Jul. 2001, pp. 55-61.
Konno R et al: “Detection of human papillomavirus DNA . . . ”, Tohoku Journal of Experimental Medicine, Japan, vol. 168, No. 3, Nov. 1992, pp. 491-497.
Choo K B et al: “Integration of human papillomavirus type 16 . . . ”, Virology, US, vol. 161, No. 1, Nov. 1987, pp. 259-261, Abstract.
Nindl I et al: “Human papillomavirus distribution in cervical tissues . . . ”, Int. Journal of Gynecological Pathology, New York, NY, US, vol. 16, No. 3, 1997, pp. 197-204.
Klaes Ruediger et al: “Overexpression of p16INK4a as a specific marker . . . ”, International Journal of Cancer, vol. 92, No. 2, 2001, pp. 276-284.
Wiest Tina et al: “Involvement of intact HPV16 E6/E/7 gene expression . . . ”, Oncogene, vol. 21, No. 10, Feb. 2002, pp. 1510-1517, Abstract.
Sdek Patima et al: “Influence of HPV16 on expression of RB . . . ”, Chinese Journal of Stomatology, China, vol. 37, No. 2, Mar. 2002, pp. 84-86, Abstract.
Bullwinkel et al., “Ki-67 Protein is Associated with Ribosomal RNA Transcription in Quiescent and Proliferating Cells,”J. Cell Physiol., vol. 206, No. 3, 624-635 (2006).
Martin et al., “Expression of p16/INK4a in Posttransplantation Lymphoproliferative Disorders,”Am. J. Pathol., vol. 156, No. 5, 1573-1579 (2000).
Dai et al., “p16INK4aExpression Begins Early in Human Colon Neoplasia and Correlates Inversely with Markers of Cell Proliferation,”Gastroenterology, vol. 119, No. 4, 929-942 (2000).
Emig et al., “Aberrant Cytoplasmic Expression of the p16 Protein in Breast Cancer is Associated with Accelerated Tumour Proliferation,”Br. J. Cancer., vol. 78, No. 11, 1661-1668 (1998).
Bepler et al., “Mcm2: A Novel Diagnostic Marker for Early Detection of Premalignant Lesions of the Lung,”Proceedings of the American Association for Cancer Research Annual, vol. 42, 356 (2001).
Ridder et al., “Novel Biomarkers for HPV Associated Lesions,”Gynäkologe, vol. 36, No. 4, 323-330 (2003).
Riethdorf Lutz et al., “Human Papillomaviruses, Expression of p16INK4a, and Early Endocervical Grandular Neoplasia,”Hum. Pathol., vol. 33, No. 9, 899-904 (2002).
Sanchez-Aguilera et al., “p14(ARF) Nuclear Overexpression in Aggressive B-cell Lymphomas is a Sensor of Malfunction of the Common Tumor Suppressor Pathways,”Blood, vol. 99, No. 4, 1411-1418 (2002).
Simonart et al., “Antiproliferative and Apoptotic Effects of Iron Chelators on Human Cervical Carcinoma Cells,”Gynecol. Oncol., vol. 85, No. 1, 95-102 (2002).
Von Knebel et al., “New Markers to Identify HPV-Transformed Dysplastic Cervical Epithelia,”Acta Cytol., vol. 46, No. 1, Supplement, 156 (2002).
Klaes et al., “p16INK4a Immunohistochemistry Improves Interobserver Agreement in the Diagnosis of Cervical Intraepithelial Neoplasia,” Am. J. Surg. Pathol., vol. 26, No. 11, 1389-1399 (2002).
Keating et al., “Ki-67, Cyclin E, and pINK4are Complimentary Surrogate Biomakers for Human Papilloma Virus-Related Cervical Neoplasia,” Am. J. Surg. Pathol., 25, No. 7, 884-891 (2001).
Wright et al., “2006 Consensus Guidelines for the Management of Women with Abnormal Cervical Cancer Screening Test,” Am. J. Obstet. Gynecol., 346-355 (Oct. 2007).
Doeberitz Magnus Von Knebel
Martin Peter
Ridder Ruediger
Aeder Sean
Fitzpatrick ,Cella, Harper & Scinto
mtm Laboratories, AG
LandOfFree
Method for discrimination of metaplasias from neoplastic or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for discrimination of metaplasias from neoplastic or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for discrimination of metaplasias from neoplastic or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4295214